JournalsHub
.online
Find My Journal
KY

Kun‐Huei Yeh

Chung Yuan Christian University TW

ORCID 0000-0002-7306-174X
392
Publications
15,844
Citations
50
H-Index
171
i10-Index
9.44
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial OA
Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, Min‐Hee Ryu, Yee Chao +19 more
The Lancet 2017
2,255
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma +15 more
The Lancet Oncology 2015
800
p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27 OA
Lyuben Tsvetkov, Kun‐Huei Yeh, Soo-Jung Lee, Hong Sun, Hui Zhang
Current Biology 1999
787
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve A. Lowery, Rachna T. Shroff, Karl Heinz Weiss, Christoph Springfeld +24 more
Journal of Clinical Oncology 2017
709
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study OA
Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Guoping Sun, Toshihiko Doi +14 more
Journal of Clinical Oncology 2014
619

Publications

387 total

ctDNA-based molecular residual disease and survival in resectable colorectal cancer PDF

Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, Keiji Hirata, Kozo Kataoka et al. - Nature Medicine, 2024
Cited by 158 OpenAlex

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C

Marwan Fakih, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo et al. - New England Journal of Medicine, 2023
Cited by 312 OpenAlex

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data PDF

Li‐Tzong Chen, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato et al. - Gastric Cancer, 2019
Cited by 227 OpenAlex

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Kei Muro, Florian Lordick, Takahiro Tsushima, George Pentheroudakis, Eishi Baba et al. - Annals of Oncology, 2018
Cited by 284 OpenAlex

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS PDF

Kei Muro, Eric Van Cutsem, Yukiya Narita, George Pentheroudakis, Eishi Baba et al. - Annals of Oncology, 2018
Cited by 219 OpenAlex

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial PDF

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, Min‐Hee Ryu, Yee Chao et al. - The Lancet, 2017
Cited by 2,255 OpenAlex

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle, Maeve A. Lowery, Rachna T. Shroff, Karl Heinz Weiss, Christoph Springfeld et al. - Journal of Clinical Oncology, 2017
Cited by 709 OpenAlex

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS PDF

Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, George Pentheroudakis, Kentaro Yamazaki et al. - Annals of Oncology, 2017
Cited by 584 OpenAlex

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma et al. - The Lancet Oncology, 2015
Cited by 800 OpenAlex

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study PDF

Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Guoping Sun, Toshihiko Doi et al. - Journal of Clinical Oncology, 2014
Cited by 619 OpenAlex

Research Topics

Colorectal Cancer Treatments and Studies (121) Gastric Cancer Management and Outcomes (110) Cancer Treatment and Pharmacology (46) Lung Cancer Treatments and Mutations (43) Genetic factors in colorectal cancer (40)

Frequent Co-Authors

KE
Kei Muro
6 joint publications
LI
Li‐Tzong Chen
5 joint publications
MI
Min‐Hee Ryu
4 joint publications
HY
Hyun Cheol Chung
4 joint publications
ER
Eric Van Cutsem
4 joint publications
TA
Takayuki Yoshino
4 joint publications

Affiliations

National Taipei University of Technology
TW 2013 - 2013
Obayashi (Japan)
JP 2014 - 2014
Memorial Hospital of South Bend
US 2005 - 2005
Apple (Israel)
IL 2015 - 2015
The University of Texas MD Anderson Cancer Center
US 2017 - 2017

External Profiles

OpenAlex Profile Search Semantic Scholar ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now